Scientific letters

Adrenal suppression and Cushing’s syndrome secondary to ritonavir and budesonide

D Gray, P Roux, M Carrihill, M Klein

Abstract


Ritonavir is a protease inhibitor used in combination therapy for advanced HIV infection. In South Africa lopinavir/ritonavir is first-line therapy for children under 3 years of age where there is a history of perinatal exposure to the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine. Ritonavir is a potent inhibitor of hepatic cytochrome P450-CYP3A4 iso-enzyme activity.

Inhaled or intranasal corticosteroids are commonly used in children with recurrent lower airways obstruction, allergic rhinitis and chronic obstructive airways disease. Although systemic absorption of inhaled corticosteroids occurs, side-effects are uncommon at low or medium doses.

Inhaled corticosteroids are metabolised by hepatic CYP3A4. Fluticasone, a corticosteroid used in children, is known to interact with ritonavir, resulting in high levels of corticosteroids, suppression of the adrenocortical axis and Cushing’s syndrome. There have been no reports of other inhaled corticosteroids causing adrenal suppression and Cushing’s syndrome. Budesonide and beclomethasone are reported to be associated with a lower risk of systemic side-effects than fluticasone, and a literature review suggested that they be used as an alternative to fluticasone given the risk of suppression of the adrenocortical axis.

We report 3 cases of children presenting with a suppressed adrenocortical axis and Cushing’s syndrome as a consequence of budesonide and ritonavir co-therapy.

Authors' affiliations

D Gray, School of Child and Adolescent Health, University of Cape Town

P Roux,

M Carrihill,

M Klein,

Full Text

PDF (443KB)

Keywords

Cushing Syndrom; ritonavir; budesonide; HIV infection; children

Cite this article

South African Medical Journal 2010;100(5):296-297.

Article History

Date submitted: 2009-10-20
Date published: 2010-05-04

Article Views

Abstract views: 1668
Full text views: 1343

Comments on this article

*Read our policy for posting comments here